Story perspectives

Eli Lilly Beats Estimates, Raises 2026 Sales Outlook

By Drooid · Oct 29, 2026 · How we work

Read the story

Story summary

Summary

Eli Lilly reported third-quarter revenue of $24.4 billion, topping the $22.61 billion estimate.
The company lifted its 2026 sales outlook to $91-$92 billion from $85-$87 billion.
Shares rose about 4% in pre-market trading after the earnings release.
Lilly held 63% of the U.S. obesity-diabetes market, versus Novo’s 36.6%.
Around 500,000 Medicare patients accessed Lilly’s obesity drugs through the Bridge program.

1 of 1

Eli Lilly reported third-quarter revenue of $24.4 billion, topping the $22.61 billion estimate.
The company lifted its 2026 sales outlook to $91-$92 billion from $85-$87 billion.
Shares rose about 4% in pre-market trading after the earnings release.
Lilly held 63% of the U.S. obesity-diabetes market, versus Novo’s 36.6%.
Around 500,000 Medicare patients accessed Lilly’s obesity drugs through the Bridge program.